Phase 4
Completed N=19
Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
Source: ClinicalTrials.gov NCT04352439 ↗Enrolled (actual)
19
Serious AEs
31.6%
Results posted
Sep 2022
Primary outcomePrimary: Number of Participants Experiencing a Venous Thromboembolism — 4 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Experiencing a Venous Thromboembolism |
4 | — |
| PRIMARY Number of Participants With at Least One Adverse Event |
— | — |
| PRIMARY Medication Adherence |
— | — |
Eligibility Criteria
Inclusion Criteria
- Khorana score = 1
- Over age 18
- English-speaking female patients
- Able to consent
- Receiving neoadjuvant chemotherapy Cancer of primary ovarian, fallopian tube, mullerian, or peritoneal origin
Exclusion Criteria
- Allergy or intolerance to study medication
- Indication for a non-aspirin form of antiplatelet (i.e. cardiac stent)
- Already on alternative form of anticoagulation
- Active bleeding
- High risk for active bleeding (i.e. recent intracranial bleed or gastrointestinal bleed, known brain metastases)
- Thrombocytopenia (platelets <50,000)
- Unable to complete medication adherence diary
- Unable to take oral medications
Data sourced from ClinicalTrials.gov (NCT04352439). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.